Department of Medical Biometry, University of Tübingen, Tübingen, Germany.
PLoS Negl Trop Dis. 2011 Nov;5(11):e1405. doi: 10.1371/journal.pntd.0001405. Epub 2011 Nov 29.
In the Indian subcontinent, about 200 million people are at risk of developing visceral leishmaniasis (VL). In 2005, the governments of India, Nepal and Bangladesh started the first regional VL elimination program with the aim to reduce the annual incidence to less than 1 per 10,000 by 2015. A mathematical model was developed to support this elimination program with basic quantifications of transmission, disease and intervention parameters. This model was used to predict the effects of different intervention strategies.
Parameters on the natural history of Leishmania infection were estimated based on a literature review and expert opinion or drawn from a community intervention trial (the KALANET project). The transmission dynamic of Leishmania donovani is rather slow, mainly due to its long incubation period and the potentially long persistence of parasites in infected humans. Cellular immunity as measured by the Leishmanin skin test (LST) lasts on average for roughly one year, and re-infection occurs in intervals of about two years, with variation not specified. The model suggests that transmission of L. donovani is predominantly maintained by asymptomatically infected hosts. Only patients with symptomatic disease were eligible for treatment; thus, in contrast to vector control, the treatment of cases had almost no effect on the overall intensity of transmission.
Treatment of Kala-azar is necessary on the level of the individual patient but may have little effect on transmission of parasites. In contrast, vector control or exposure prophylaxis has the potential to efficiently reduce transmission of parasites. Based on these findings, control of VL should pay more attention to vector-related interventions. Cases of PKDL may appear after years and may initiate a new outbreak of disease; interventions should therefore be long enough, combined with an active case detection and include effective treatment.
在印度次大陆,约有 2 亿人面临罹患内脏利什曼病(VL)的风险。2005 年,印度、尼泊尔和孟加拉国政府启动了首个区域 VL 消除计划,目标是到 2015 年将年发病率降低至每 10000 人以下。为支持这一消除计划,开发了一个数学模型,对传播、疾病和干预参数进行了基本量化。该模型用于预测不同干预策略的效果。
基于文献回顾和专家意见或从社区干预试验(KALANET 项目)中得出了利什曼原虫感染自然史的参数。利什曼原虫的传播动态较为缓慢,主要是由于其潜伏期长,以及感染人体中寄生虫的潜在长期存在。细胞免疫(通过利什曼素皮肤试验[LST]测量)平均持续约一年,再次感染发生在大约两年的间隔内,但未指定变异。该模型表明,利什曼原虫的传播主要由无症状感染宿主维持。只有出现症状的患者才有资格接受治疗;因此,与病媒控制不同,病例治疗对总体传播强度几乎没有影响。
治疗 kala-azar 在个体患者层面是必要的,但可能对寄生虫的传播影响不大。相比之下,病媒控制或暴露预防有潜力有效降低寄生虫的传播。基于这些发现,VL 控制应更加关注与病媒相关的干预措施。PKDL 病例可能在数年后出现,并可能引发新的疾病爆发;因此,干预措施应足够长,结合主动病例发现,并包括有效治疗。